Imagene Reports FY25 Revenue of $800K, IMG-007 Leading in Clinical Development
Reports FY25 revenue $800k vs $3.5M last year. "IMG-007 is now the leading receptor-targeting OX40 antagonist program in clinical development. Our approach is entirely unlike that of ADCC-enhanced anti-OX40 antibodies such as rocatinlimab: published data has shown rocatinlimab treatment causes deep depletion of T cells, while IMG-007 is a non-T cell depleting antibody. This is a fundamental, intentional, and critical difference in our molecule's design," commented Kristin Yarema, PhD, Chief Executive Officer of Imagene. "While the clinical profile of IMG-007 remains early, our safety database continues to grow and we have not seen any of the tolerability issues mechanistically linked to T cell depletion -- pyrexia, chills, ulcers -- nor have we seen any malignancies. This emerging clinical profile adds to the compelling, competitive efficacy we saw in our proof-of-concept studies in atopic dermatitis and alopecia areata. We are confident that ADAPTIVE, our Phase 2b dose-ranging study in AD, is robust and designed to well characterize IMG-007's efficacy, safety, and convenience for patients."
Trade with 70% Backtested Accuracy
Analyst Views on IMA
About IMA
About the author
ImageneBio Reports Increased Net Loss in FY Results
- Financial Performance: ImageneBio reported a GAAP EPS of -$9.64 for FY 2025, indicating ongoing challenges in profitability and reflecting pressure in market competition.
- Cash Position: As of December 31, 2025, the company had $135.3 million in cash, cash equivalents, and marketable securities, a significant increase from $12.1 million as of December 31, 2024, indicating improved financial management.
- Increased Net Loss: The net loss for Q4 2025 was $6.9 million, up from $4.8 million in Q4 2024, with the $2.1 million increase attributed to higher operating costs following the merger and associated transaction costs, highlighting financial strain during integration.
- Rising Operating Costs: The additional operating costs due to the merger place a heavier financial burden on ImageneBio, which may impact its future investment capacity and competitive position in the market.
Imagene Appoints New Chief Medical Officer to Drive Clinical Development
- New Chief Medical Officer: ImageneBio has appointed Dr. Ben Porter-Brown as Chief Medical Officer, who brings over 20 years of clinical development experience in autoimmune and inflammatory diseases, focusing on executing the Phase 2b ADAPTIVE trial to enhance the company's expertise in this area.
- International Trial Expansion: Dr. Porter-Brown plans to expand the Phase 2b trial footprint with international sites in the UK and Europe, which will not only aid in patient recruitment but also enhance Imagene's competitiveness in the global market.
- Innovative Treatment Potential: Imagene's IMG-007 is a monoclonal antibody targeting OX40 with unique product features, expected to provide new treatment options for patients with moderate-to-severe atopic dermatitis, filling a market gap and driving future growth for the company.
- Equity Incentive Plan: As an inducement for joining, Imagene will grant Dr. Porter-Brown 137,000 shares of common stock, reflecting the company's commitment to his leadership and aiming to attract top talent to drive the success of clinical projects.
Albemarle Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Analyst Ratings Overview: Top Wall Street analysts have recently changed their outlook on several companies, with a focus on upgrades, downgrades, and new coverage initiations.
The Pennant Group, Inc.: Jefferies analyst Brian Tanquilut initiated coverage with a Buy rating and a price target of $30, while shares closed at $24.48.
Alphatec Holdings, Inc.: JP Morgan analyst Allen Gong initiated coverage with an Overweight rating and a price target of $19, with shares closing at $15.89.
ImageneBio, Inc. and Albemarle Corporation: Leerink Partners initiated coverage on ImageneBio with an Outperform rating and a $30 price target, while Rothschild & Co initiated coverage on Albemarle with a Buy rating and a $135 price target.
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio's Executive Compensation: ImageneBio, Inc. granted Dr. Kristin Yarema, the new CEO, inducement stock options for 436,080 shares and restricted stock units for 153,505 shares as part of her employment agreement, with specific vesting schedules over four years.
Company Overview: ImageneBio is focused on developing treatments for immunological and inflammatory diseases, with its lead asset IMG-007 currently undergoing a Phase 2b clinical trial for moderate-to-severe atopic dermatitis.
ImageneBio Reports Increased Net Loss in FY Results
- Financial Performance: ImageneBio reported a GAAP EPS of -$9.64 for FY 2025, indicating ongoing challenges in profitability and reflecting pressure in market competition.
- Cash Position: As of December 31, 2025, the company had $135.3 million in cash, cash equivalents, and marketable securities, a significant increase from $12.1 million as of December 31, 2024, indicating improved financial management.
- Increased Net Loss: The net loss for Q4 2025 was $6.9 million, up from $4.8 million in Q4 2024, with the $2.1 million increase attributed to higher operating costs following the merger and associated transaction costs, highlighting financial strain during integration.
- Rising Operating Costs: The additional operating costs due to the merger place a heavier financial burden on ImageneBio, which may impact its future investment capacity and competitive position in the market.
Imagene Appoints New Chief Medical Officer to Drive Clinical Development
- New Chief Medical Officer: ImageneBio has appointed Dr. Ben Porter-Brown as Chief Medical Officer, who brings over 20 years of clinical development experience in autoimmune and inflammatory diseases, focusing on executing the Phase 2b ADAPTIVE trial to enhance the company's expertise in this area.
- International Trial Expansion: Dr. Porter-Brown plans to expand the Phase 2b trial footprint with international sites in the UK and Europe, which will not only aid in patient recruitment but also enhance Imagene's competitiveness in the global market.
- Innovative Treatment Potential: Imagene's IMG-007 is a monoclonal antibody targeting OX40 with unique product features, expected to provide new treatment options for patients with moderate-to-severe atopic dermatitis, filling a market gap and driving future growth for the company.
- Equity Incentive Plan: As an inducement for joining, Imagene will grant Dr. Porter-Brown 137,000 shares of common stock, reflecting the company's commitment to his leadership and aiming to attract top talent to drive the success of clinical projects.
Albemarle Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Analyst Ratings Overview: Top Wall Street analysts have recently changed their outlook on several companies, with a focus on upgrades, downgrades, and new coverage initiations.
The Pennant Group, Inc.: Jefferies analyst Brian Tanquilut initiated coverage with a Buy rating and a price target of $30, while shares closed at $24.48.
Alphatec Holdings, Inc.: JP Morgan analyst Allen Gong initiated coverage with an Overweight rating and a price target of $19, with shares closing at $15.89.
ImageneBio, Inc. and Albemarle Corporation: Leerink Partners initiated coverage on ImageneBio with an Outperform rating and a $30 price target, while Rothschild & Co initiated coverage on Albemarle with a Buy rating and a $135 price target.
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio's Executive Compensation: ImageneBio, Inc. granted Dr. Kristin Yarema, the new CEO, inducement stock options for 436,080 shares and restricted stock units for 153,505 shares as part of her employment agreement, with specific vesting schedules over four years.
Company Overview: ImageneBio is focused on developing treatments for immunological and inflammatory diseases, with its lead asset IMG-007 currently undergoing a Phase 2b clinical trial for moderate-to-severe atopic dermatitis.
